Creative Biolabs Expands Delivery Platforms for Innovative Bioconjugates and LNP Technologies

The company optimizes conjugation chemistry and formulation pipelines to enhance targeted delivery and stability for gene therapy research.

Mar. 24, 2026 at 6:08am

Got story updates? Submit your updates here. ›

Creative Biolabs, a leading contract research organization, announces the expansion of its bioconjugation and lipid nanoparticle (LNP) platforms to address the growing demand for stable and efficient delivery vehicles in gene therapy research. The company's focus on antibody-siRNA conjugates (ARCs) and advanced LNP formulations aims to improve targeted delivery and minimize off-target effects, particularly in oncology and rare genetic disorders.

Why it matters

As the therapeutic landscape evolves, the need for cell-specific targeting and enhanced delivery has become crucial for the success of gene therapies. Creative Biolabs' advancements in bioconjugation and LNP technologies address these challenges, potentially unlocking new possibilities for researchers working on innovative treatments.

The details

Creative Biolabs has refined its selection of linkers and conjugation sites to ensure the stability of siRNA payloads during circulation while maintaining the antibody's binding affinity in ARCs. The company has also expanded its expertise in LNP conjugation services, allowing for the surface modification of nanoparticles with ligands or antibodies for targeted delivery. Additionally, Creative Biolabs emphasizes a data-driven approach to custom formulation, systematically screening lipid ratios, buffer conditions, and conjugation methodologies to identify the most stable configuration for a given payload.

  • Creative Biolabs announced the expansion of its bioconjugation and LNP platforms on March 24, 2026.

The players

Creative Biolabs

A premier contract research organization (CRO) with years of experience in gene therapy delivery solutions, providing high-quality products and specialized services to academic institutions and pharmaceutical companies worldwide.

Professor A. Sharma

A researcher who praised the technical team at Creative Biolabs for their expertise in siRNA chemical modification and the design and synthesis of a novel 2'-O-methyl-modified siRNA payload that was successfully conjugated to a proprietary antibody fragment, resulting in an ARC with excellent nuclease resistance and a 3-fold increase in gene knockdown efficiency in primary cells.

Got photos? Submit your photos here. ›

What they’re saying

“The team's expertise in siRNA chemical modification is invaluable. They designed and synthesized a novel 2'-O-methyl-modified siRNA payload and successfully conjugated it to our proprietary antibody fragment. The resulting ARC exhibited excellent nuclease resistance and a 3-fold increase in gene knockdown efficiency in primary cells. Their data quality is unparalleled.”

— Professor A. Sharma

“The industry is currently moving from first-generation delivery systems to more complex, multi-functional architectures. By optimizing the custom formulation process, we can control the pharmacokinetic properties of these particles, ensuring they reach the target cytoplasm with high encapsulation efficiency and structural integrity.”

— Senior Scientist, at Creative Biolabs

The takeaway

Creative Biolabs' advancements in bioconjugation and LNP technologies demonstrate the company's commitment to providing innovative solutions that address the evolving needs of gene therapy research, particularly in the areas of targeted delivery and enhanced stability of therapeutic payloads.